2 results
Approved WMORecruiting
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
Approved WMOCompleted
The objective is to study the effect of beta-agonist and beta-antagonist treatment on human bone remodeling.